ArticleNeurosurgical review2025
Analysis of the effect of platelet function and different doses of ticagrelor after flow diverter treatment of intracranial aneurysms.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Half-dose ticagrelor versus clopidogrel dual antiplatelet therapy in flow diverter-treated intracranial aneurysms: analysis of platelet reactivity and perioperative safety outcomes.Acta neurochirurgica · 2026Article
- Tubridge flow diverter for the treatment of dissecting aneurysms in the middle cerebral artery.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Ticagrelor has become the standard drug for the treatment of intracranial aneurysms (IAs) with flow diverters (FDs), but the dosage has not been standardized. The effect of platelet function on clinical and imaging prognosis remains unclear. This study aimed to show the effects of different doses of ticagrelor and platelet aggregation function on the clinical and imaging prognosis after FDs treatment of aneurysms. Patients with IAs and underwent FDs stenting were recruited between July 2019 and June 2023. Logistic regression was performed to assess the predictors of incomplete occlusion and in-stent stenosis (ISS). Linear regression analysis, scatter plot and violin diagram were used to investigate the predictors of maximum platelet aggregation rate induced by ADP (ADP-MPA). The study included 156 patients with 206 aneurysms. There was no significant difference in clinical prognosis and aneurysm occlusion rates between the standard-dose group (ticagrelor, 90 mg/bid) and the low-dose group (ticagrelor, 45 mg/bid). Multivariable analysis identified the ADP-MPA ≥ ADP-MPA (median) (24.2%) (p = 0.037) as an independent risk factor for incomplete occlusion of aneurysms. In addition, higher ADP-MPA (p = 0.045) was an independent risk factor for ISS. Uric acid level (p = 0.019) was negatively associated with ADP-MPA, whereas age (p = 0.031) and body mass index (BMI) (p = 0.042) were positively associated with ADP-MPA. The differences of clinical prognosis and aneurysm occlusion rates between the standard-dose group and the low-dose group were not significant for the treatment of aneurysms with FDs. Higher ADP-MPA predicted higher rates of incomplete occlusion and in-stent stenosis. Uric acid level was negatively associated with ADP-MPA, whereas age and BMI were positively associated with ADP-MPA.
Indexed as
Identifiers
39870937What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.